Antibody-drug conjugates in lung cancer: dawn of a new era?Niamh Coleman(The University of Texas MD Anderson Cancer Center), Xiuning Le(The University of Texas MD Anderson Cancer Center)npj Precision OncologyJanuary 11, 202310.1038/s41698-022-00338-9Cited by 116SaveCiteExport RISWatch citationsRelated PapersFirst-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC|Clinical Cancer Research|2025|6